|
1
|
Kune GA, Kune S and Watson LF: Colorectal
cancer risk, chronic illnesses, operations and medications: Case
control results from the melbourne colorectal cancer study. Cancer
Res. 48:4399–4404. 1988.PubMed/NCBI
|
|
2
|
Majumdar SR, Fletcher RH and Evans AT: How
does colorectal cancer present?; symptoms, duration, and clues to
location. Am J Gastroenterol. 94:3039–3045. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Bouvier AM, Foschi R, Hackl M,
Larsen IK, Lemmens V, Mangone L and Francisci S: Progress in
colorectal cancer survival in Europe from the late 1980s to the
early 21st century: The EUROCARE study. Int J Cancer.
131:1649–1658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cianchi F, Cortesini C, Bechi P, Fantappiè
O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R
and Masini E: Up-regulation of cyclooxygenase 2 gene expression
correlates with tumor angiogenesis in human colorectal cancer.
Gastroenterology. 121:1339–1347. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikenoue T, Kanai F, Hikiba Y, Obata T,
Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, et al:
Functional analysis of PIK3CA gene mutations in human colorectal
cancer. Cancer Res. 65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith G, Carey FA, Beattie J, Wilkie MJ,
Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf CR:
Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways
to colorectal cancer. Proc Natl Acad Sci USA. 99:9433–9438. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki H, Watkins DN, Jair KW, Schuebel
KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, van
Engeland M, et al: Epigenetic inactivation of SFRP genes allows
constitutive WNT signaling in colorectal cancer. Nat Genet.
36:417–422. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui H, Cruz-Correa M, Giardiello FM,
Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and
Feinberg AP: Loss of IGF2 imprinting: A potential marker of
colorectal cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khamas A, Ishikawa T, Shimokawa K, Mogushi
K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara
K: Screening for epigenetically masked genes in colorectal cancer
Using 5-Aza-2′-deoxycytidine, microarray and gene expression
profile. Cancer Genomics-Proteomics. 9:67–75. 2012.PubMed/NCBI
|
|
11
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smyth GK: Limma: Linear models for
microarray dataBioinformatics and computational biology solutions
using R and bioconductor. Springer; pp. 397–420. 2005, View Article : Google Scholar
|
|
13
|
Hamosh A, Scott AF, Amberger JS, Bocchini
CA and McKusick VA: Online Mendelian Inheritance in Man (OMIM), a
knowledgebase of human genes and genetic disorders. Nucleic acids
Res. 33:D514–D517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic acids
Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang H and Gough J: A
disease-drug-phenotype matrix inferred by walking on a functional
domain network. Mol Biosyst. 9:1686–1696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang H and Gough J: The ‘dnet’ approach
promotes emerging research on cancer patient survival. Genome Med.
6:642014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sherman BT, da W Huang, Tan Q, Guo Y, Bour
S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID
Knowledgebase: A gene-centered database integrating heterogeneous
gene annotation resources to facilitate high-throughput gene
functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hulsegge I, Kommadath A and Smits MA:
Globaltest and GOEAST: Two different approaches for Gene Ontology
analysis. BMC Proc. 3 Suppl 4:S102009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ogata H, Goto S, Sato K, Fujibuchi W, Bono
H and Kanehisa M: KEGG: Kyoto encyclopedia of genes and genomes.
Nucleic acids Res. 27:29–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Griffith M, Griffith OL, Coffman AC,
Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB,
Eldred JM, et al: DGIdb: Mining the druggable genome. Nat Methods.
10:1209–1210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lai1 EY, Chen ZG, Zhou X, Fan XR, Wang H,
Lai PL, Su YC, Zhang BY, Bai XC and Li YF: DEPTOR Expression
negatively correlates with mTORC1 activity and tumor progression in
colorectal cancer. Asian Pac J Cancer Prev. 15:4589–4594. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Francipane MG and Lagasse E: mTOR pathway
in colorectal cancer: An update. Oncotarget. 5:492014.PubMed/NCBI
|
|
23
|
Grünhage F, Jungck M, Lamberti C, Berg C,
Becker U, Schulte-Witte H, Plassmann D, Rahner N, Aretz S,
Friedrichs N, et al: Association of familial colorectal cancer with
variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int
J Colorectal Dis. 23:147–154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lewis RC, Bostick RM, Xie D, Deng Z,
Wargovich MJ, Fina MF, Roufail WM and Geisinger KR: Polymorphism of
the cyclin D1 gene, CCND1, and risk for incident sporadic
colorectal adenomas. Cancer Res. 63:8549–8553. 2003.PubMed/NCBI
|
|
25
|
Zhang W, Gordon M, Press OA, Rhodes K,
Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE,
et al: Cyclin D1 and epidermal growth factor polymorphisms
associated with survival in patients with advanced colorectal
cancer treated with Cetuximab. Pharmacogenet Genomics. 16:475–483.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goos JA, Coupe VM, Diosdado B, Delis-Van
Diemen PM, Karga C, Beliën JA, Carvalho B, van den Tol MP, Verheul
HM, Geldof AA, et al: Aurora kinase A (AURKA) expression in
colorectal cancer liver metastasis is associated with poor
prognosis. Br J Cancer. 109:2445–2452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et
al: A homologue of Drosophila aurora kinase is oncogenic and
amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hermsen M, Postma C, Baak J, Weiss M,
Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W,
et al: Colorectal adenoma to carcinoma progression follows multiple
pathways of chromosomal instability. Gastroenterology.
123:1109–1119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aust DE, Muders M, Köhler A, Schmidt M,
Diebold J, Müller C, Löhrs U, Waldman FM and Baretton GB:
Prognostic relevance of 20q13 gains in sporadic colorectal cancers:
A FISH analysis. Scand J Gastroenterol. 39:766–772. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakao K, Mehta KR, Fridlyand J, Moore DH,
Jain AN, Lafuente A, Wiencke JW, Terdiman JP and Waldman FM:
High-resolution analysis of DNA copy number alterations in
colorectal cancer by array-based comparative genomic hybridization.
Carcinogenesis. 25:1345–1357. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Postma C, Terwischa S, Hermsen MA, Van der
Sijp JR and Meijer GA: Gain of chromosome 20q is an indicator of
poor prognosis in colorectal cancer. Cell Oncol. 29:73–75.
2007.PubMed/NCBI
|
|
32
|
Carvalho B, Postma C, Mongera S, Hopmans
E, Diskin S, van De Wiel MA, Van Criekinge W, Thas O, Matthäi A,
Cuesta MA, et al: Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progression.
Gut. 58:79–89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sillars-Hardebol AH, Carvalho B, De Wit M,
Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van De Wiel MA,
Meijer GA and Fijneman RJ: Identification of key genes for
carcinogenic pathways associated with colorectal
adenoma-to-carcinoma progression. Tumour Biol. 31:89–96. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Correa RG, De Carvalho AF, Pinheiro NA,
Simpson AJ and De Souza SJ: NABC1 (BCAS1): Alternative splicing and
downregulation in colorectal tumors. Genomics. 65:299–302. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SH, Xia D, Kim SW, Holla V, Menter DG
and DuBois RN: Human enhancer of filamentation 1 is a mediator of
hypoxia-inducible factor-1alpha-mediated migration in colorectal
carcinoma cells. Cancer Res. 70:4054–4063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Singh MK, Cowell L, Seo S, O'Neill G and
Golemis E: Molecular basis for HEF1/NEDD9/Cas-L action as a
multifunctional co-ordinator of invasion, apoptosis and cell cycle.
Cell Biochem Biophys. 48:54–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xia D, Holla VR, Wang D, Menter DG and
DuBois RN: HEF1 is a crucial mediator of the proliferative effects
of prostaglandin E(2) on colon cancer cells. Cancer Res.
70:824–831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yeh JJ, Routh ED, Rubinas T, Peacock J,
Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO and Der CJ:
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for
MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther.
8:834–843. 2009. View Article : Google Scholar : PubMed/NCBI
|
